VIVUS (VVUS), Auxilium Announce Extension of STENDRA License Termination Data
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
VIVUS, Inc. (Nasdaq: VVUS) and Auxilium Pharmaceuticals, Inc., a subsidiary of Endo International plc (Nasdaq: ENDP) announced an extension of the termination date of the license agreement between Auxilium and VIVUS for STENDRA® (avanafil) U.S. and Canadian commercial rights through September 30, 2016.
"We have been working closely with Auxilium to ensure a smooth transition of STENDRA back to VIVUS," said Seth H. Z. Fischer, VIVUS Chief Executive Officer. "Through this process, we have determined that a handoff of STENDRA at the end of a calendar quarter provides the most efficient cut-off date for our internal processes, customers and vendors. We are concurrently preparing to commercialize STENDRA in the U.S. while maintaining discussions to license or sell STENDRA's U.S. commercialization rights."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rexahn Pharma (RNN) Announces Receipt of U.S. Patent Related to RX-21101
- Dynavax (DVAX) Announces Significant Subgroup Data from HEPLISAV-B Phase 3
- Ultragenyx Pharma (RARE) Commences KRN23 Phase 3 in XLH
Create E-mail Alert Related CategoriesCorporate News, Litigation, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!